arginyl-glycyl-aspartic acid has been researched along with Pyrexia in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Badami, D; Cheng, LF; Deng, SM; Gao, B; Hong, RY; Huang, M; Zheng, SW | 1 |
| Cerullo, V; Diaconu, I; Dotti, G; Escutenaire, S; Guse, K; Haavisto, E; Hannuksela, P; Hemminki, A; Holm, SL; Joensuu, T; Kanerva, A; Kangasniemi, L; Karioja-Kallio, A; Karli, E; Kauppinen, S; Laasonen, L; Nokisalmi, P; Oksanen, M; Partanen, K; Pesonen, S; Raki, M | 1 |
1 trial(s) available for arginyl-glycyl-aspartic acid and Pyrexia
| Article | Year |
|---|---|
Integrin targeted oncolytic adenoviruses Ad5-D24-RGD and Ad5-RGD-D24-GMCSF for treatment of patients with advanced chemotherapy refractory solid tumors.
Topics: Adenoviridae; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; DNA, Viral; Drug Resistance, Neoplasm; Fatigue; Female; Fever; Genetic Vectors; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Integrins; Male; Middle Aged; Neoplasms; Oligopeptides; Oncolytic Virotherapy; Oncolytic Viruses; Real-Time Polymerase Chain Reaction; Treatment Outcome; Viral Load; Virus Replication | 2012 |
1 other study(ies) available for arginyl-glycyl-aspartic acid and Pyrexia
| Article | Year |
|---|---|
RGD-conjugated iron oxide magnetic nanoparticles for magnetic resonance imaging contrast enhancement and hyperthermia.
Topics: Cell Line; Cell Line, Tumor; Contrast Media; Ferric Compounds; Fever; Humans; Magnetic Resonance Imaging; Magnetics; Microscopy, Electron, Transmission; Nanoparticles; Oligopeptides; Prohibitins | 2014 |